text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 144689-24-7 | Product Number: O0507

Olmesartan


Purity: >98.0%(HPLC)
Chemical Substance Law (ENCS):   5-6559
Synonyms:
Product Documents:
100MG
¥9,800
≥40  6   Contact Us
* Available Stock: Prompt shipment (for products) in Saitama/Hyogo warehouse. Stock In Other WH: Shipment in about 2-3 Business Days from Saitama warehouse. Please contact us if you need further information.
* The displayed price is the unit price and does not include consumption tax. The unit prices displayed are the latest and are subject to change without notice.
* To send your quote request for bulk quantities, please click on the "Request Bulk Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.

Product Number O0507
Purity / Analysis Method >98.0%(HPLC)
Molecular Formula / Molecular Weight C__2__4H__2__6N__6O__3 = 446.51 
Physical State (20 deg.C) Solid
Storage Temperature Frozen (<0°C)
Condition to Avoid Heat Sensitive
Packaging and Container 100MG-Glass Bottle with Plastic Insert (View image)
CAS RN 144689-24-7
Reaxys Registry Number 7502669
PubChem Substance ID 354335584
MDL Number

MFCD00914967

Specifications
Appearance White to Light yellow powder to crystal
Purity(HPLC) min. 98.0 area%
Purity(Neutralization titration) min. 95.0 %
Properties (reference)
Melting Point 177 °C(dec.)
GHS
Related Laws:
Chemical Substance Law (ENCS) 5-6559
RTECS# NI4014100
Transport Information:
Application
Olmesartan: A Selective AT1 Subtype Angiotensin II Receptor Antagonist (“sartan”)

Olmesartan, an active metabolite of olmesartan medoxomil [O0510], is a selective AT1 subtype angiotensin II receptor antagonist (“sartan”), such as candesartan [C2635], eprosartan [E1161], irbesartan [I0859], losartan [L0232], olmesartan [O0507], telmisartan [T2861] and valsartan [V0112].
Angiotensin II is formed from angiotensin I in a reaction catalyzed by angio-tensin converting angiotensin conversion enzyme (ACE), and can active two different receptors, AT1 and AT2, both of which are coupled to G-protein. The vasopressor actions of angiotensin II are mediated through AT1 receptors. Olmesartan and sartans bind selectively to AT1 receptor with almost no binding to AT2 receptor in vascular smooth muscle. Therefore, olmesartan and sartans show blood pressure lowering effect. Recently, some combination agents with a calcium channel antagonist (e.g. amlodipine [A2353], azelnidipine [A2433]) are also used for the treatment of hypertension and cardiovascular disease. (The product is for research purpose only.)

References


PubMed Literature


TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The product with the lot number searched for has been discontinued and no related documentation is available.

Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.

A sample C of A for this product is not available at this time.

Analytical Charts
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The requested analytical chart is not available. Sorry for the inconvenience.

The product with the lot number searched for has been discontinued and no related documentation is available.

Other Documents

Session Status
Your session will timeout in 10 minutes. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page. minute. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page.

Your session has timed out. You will be redirected to the HOME page.